{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:04:29Z","timestamp":1777928669334,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to determine the efficacy of hydroxychloroquine (HCQ) in the primary thrombosis prevention of antiphospholipid antibody (aPL)-positive patients with no other systemic autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Under the auspices of Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking, a multicenter, international, randomized controlled trial (RCT) was initiated, in which persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases were randomized to receive HCQ or no treatment in addition to their standard regimen. The primary objective was the efficacy of HCQ in preventing the first thrombosis. The secondary objectives were the thrombosis incidence rate, and the effects of HCQ on aPL profile and mortality rate. Patients were risk-stratified based on antiplatelet agent use. The goal was to follow patients every 6 months for 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We recruited 20 persistently aPL-positive patients (female: 19, mean age: 46.6\u2009\u00b1\u20099.9 years, and baseline antiplatelet medication: 14); 9\/20 were randomized to HCQ. During the mean follow-up of 1.7 years, no patients developed thrombosis or a serious adverse event. The study was terminated early due to the low recruitment rate, exacerbated by the prolonged manufacturing shortage and significant price increase of HCQ in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Given that a small number of patients with a relatively short follow-up were enrolled in our RCT, and no patients developed thrombosis, we cannot accurately assess the effectiveness of HCQ for primary thrombosis prevention in persistently aPL-positive patients with no other systemic autoimmune diseases. Our experience suggests that conducting an international RCT, especially without pharmaceutical support, is an extremely challenging undertaking.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0961203317724219","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:39:51Z","timestamp":1501634391000},"page":"399-406","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":55,"title":["Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease"],"prefix":"10.1177","volume":"27","author":[{"given":"D","family":"Erkan","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Unlu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Sciascia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases\u2013Coordinating Center of Piemonte and Valle d\u2019Aosta Network for Rare Diseases, Giovanni Bosco Hospital, University of Turin, Turin, IT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Belmont","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, New York University Langone Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D Ware","family":"Branch","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Cuadrado","sequence":"additional","affiliation":[{"name":"Lupus Research Unit, St Thomas\u2019 Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology\/Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J S","family":"Knight","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Michigan Hospital, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Uthman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, American University of Beirut, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Willis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology\/Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Zhang","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Department, Peking University First Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Wahl","sequence":"additional","affiliation":[{"name":"Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Regional Universitaire de Nancy, Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Zuily","sequence":"additional","affiliation":[{"name":"Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Regional Universitaire de Nancy, Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M G","family":"Tektonidou","sequence":"additional","affiliation":[{"name":"First Department of Propaedeutic Internal Medicine, University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"key":"bibr1-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"bibr2-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1002\/art.22663"},{"key":"bibr3-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093013"},{"key":"bibr4-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306071872"},{"key":"bibr5-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2230xx"},{"key":"bibr6-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.12.4380"},{"key":"bibr7-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1177\/0961203396005001051"},{"key":"bibr8-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-213520"},{"key":"bibr9-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1002\/art.24232"},{"key":"bibr10-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312437810"},{"key":"bibr11-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0611-y"},{"key":"bibr12-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"bibr13-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"bibr14-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21591"},{"key":"bibr15-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"bibr16-0961203317724219","unstructured":"ACR-endorsed Criteria for Rheumatic Diseases 2017, www.rheumatology.org\/Practice-Quality\/Clinical-Support\/Criteria\/ACR-Endorsed-Criteria (2017, accessed 1 July 2017)."},{"key":"bibr17-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"bibr18-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307084724"},{"key":"bibr19-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096669"},{"key":"bibr20-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678919624"},{"key":"bibr21-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00060-5"},{"key":"bibr22-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01295.x"},{"key":"bibr23-0961203317724219","first-page":"1560","volume":"31","author":"Giron-Gonzalez JA","year":"2004","journal-title":"J Rheumatol"},{"key":"bibr24-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-340232"},{"key":"bibr25-0961203317724219","first-page":"2531","volume":"29","author":"Somers E","year":"2002","journal-title":"J Rheumatol"},{"key":"bibr26-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306074767"},{"key":"bibr27-0961203317724219","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.24919","volume":"60","author":"Clark C","year":"2009","journal-title":"Arthritis Rheum"},{"key":"bibr28-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO;2-C"},{"key":"bibr29-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh844"},{"key":"bibr30-0961203317724219","first-page":"372","volume":"83","author":"Silver RM","year":"1994","journal-title":"Obstet Gynecol"},{"key":"bibr31-0961203317724219","volume-title":"Designing clinical research","author":"Hulley SB","year":"2013"},{"key":"bibr32-0961203317724219","unstructured":"Guyatt G, Drummond R, Meade M, Cook D. The evidence-based medicine working group. In:\n                      Users\u2019 guides to the medical literature. Essentials of evidence-based clinical practice\n                      . Chicago, IL: McGraw Hill Education, 2008."},{"key":"bibr33-0961203317724219","unstructured":"Clinical trials\u2009-\u2009Regulation EU No 536\/2014, https:\/\/ec.europa.eu\/health\/human-use\/clinical-trials\/regulation_en (2014, accessed 9 March 2017)."},{"key":"bibr34-0961203317724219","unstructured":"Regulation (EU) No 536\/2014 of The European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC, http:\/\/eur-lex.europa.eu\/eli\/reg\/2014\/536\/oj (2014, accessed 9 March 2017)."},{"key":"bibr35-0961203317724219","unstructured":"Community register of orphan medicinal products, https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/o1820.htm \u2013 top (2017, accessed 8 March 2017)."},{"key":"bibr36-0961203317724219","unstructured":"Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation, www.ema.europa.eu\/docs\/en_GB\/document_library\/Committee_meeting_report\/2016\/12\/WC500218368.pdf (2016, accessed 8 March 2017)."},{"key":"bibr37-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"bibr38-0961203317724219","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-008-9216-2"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203317724219","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0961203317724219","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203317724219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:18:39Z","timestamp":1777677519000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0961203317724219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1177\/0961203317724219"],"URL":"https:\/\/doi.org\/10.1177\/0961203317724219","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}